Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of an oncology pharmacist-led, well-developed and validated chemotherapy order template on quality of life in breast cancer patients: A randomized controlled trial.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Clinical outcomes and safety study of CDK4/6 inhibitors in hormone-positive metastatic breast cancer - A real-world tertiary cancer center experience.

Indian journal of cancer·2026
Same author

Selective De-escalation of Axillary Surgery Post Neoadjuvant Chemotherapy in Breast Cancer-Are We Ready?

Indian journal of surgical oncology·2025
Same author

Truly Inevitable-Our Perspective on the Complications After Surgery for Rectal Cancer.

Indian journal of surgical oncology·2025
Same author

Outcomes with optimal treatment in geriatric head and neck cancers - Tertiary cancer centre experience.

Journal of cancer research and therapeutics·2024
Same author

Drug-induced Capillary Leak Syndrome.

The Journal of the Association of Physicians of India·2023

Related Experiment Video

Updated: May 16, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Systemic therapy in soft tissue sarcomas: past, present and future.

Samit Purohit1, Rohan Bhise, Sandhya Appachu

  • 1Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr M.H Marigowda road, Bangalore, -560029 India.

Indian Journal of Surgical Oncology
|December 4, 2012
PubMed
Summary

Soft tissue sarcomas (STS) require precise diagnosis for tailored chemotherapy. This review explores the evolving role of chemotherapy in STS treatment, from traditional to targeted therapies.

Keywords:
Adjuvant chemotherapySoft tissue sarcomaTrabectedin

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 16, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

  • Oncology
  • Medical Oncology
  • Cancer Research

Background:

  • Soft tissue sarcomas (STS) represent 1% of global cancer diagnoses, with over 40 subtypes.
  • Each STS subtype exhibits unique biology, clinical course, and treatment response.
  • Accurate histological diagnosis is crucial due to differential chemosensitivity.

Purpose of the Study:

  • To review the evolution of chemotherapy in soft tissue sarcoma.
  • To define the current role of chemotherapy in neoadjuvant, adjuvant, and metastatic settings.
  • To discuss emerging trends, including targeted therapies for STS.

Main Methods:

  • An extensive literature search was conducted using online and offline resources.
  • Relevant articles concerning chemotherapy in soft tissue sarcoma were identified and analyzed.
  • The review synthesizes information on the historical and current use of chemotherapy.

Main Results:

  • Chemotherapy's role in STS is increasingly specialized by histological subtype.
  • A "one size fits all" approach to chemotherapy is generally not recommended for STS.
  • Targeted therapies represent a significant area of advancement in STS treatment.

Conclusions:

  • Histological subtyping is essential for optimizing chemotherapy selection in soft tissue sarcoma.
  • Chemotherapy plays a vital, albeit specialized, role across various treatment settings for STS.
  • Future directions in STS treatment involve the integration of targeted therapies alongside traditional chemotherapy.